Andrea Dalbeni
Overview
Explore the profile of Andrea Dalbeni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
926
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ascari S, Chen R, Vivaldi C, Stefanini B, De Sinno A, Dalbeni A, et al.
Expert Rev Anticancer Ther
. 2025 Feb;
25(2):151-165.
PMID: 39913170
Introduction: The advent of immune-based combinations, primarily leveraging immune checkpoint inhibitors, has revolutionized the therapeutic landscape of hepatocellular carcinoma (HCC). The current scenario features multiple therapies that have shown superiority...
2.
Tovoli F, Pallotta D, Vivaldi C, Campani C, Federico P, Palloni A, et al.
Dig Liver Dis
. 2024 Aug;
56(12):2079-2084.
PMID: 39168753
Background: Most patients receiving atezolizumab-bevacizumab (AB) for hepatocellular carcinoma will eventually experience disease progression. Randomized clinical trials (RCTs) are undergoing to identify second-line treatments. Where RCTs are unavailable or patients...
3.
Celsa C, Cabibbo G, Fulgenzi C, Battaglia S, Enea M, Scheiner B, et al.
Hepatology
. 2024 Jul;
81(3):837-852.
PMID: 39028886
Background And Aims: Unlike other malignancies, hepatic functional reserve competes with tumor progression in determining the risk of mortality from hepatocellular carcinoma (HCC). However, the relative contribution of hepatic decompensation...
4.
Pugliese N, Polverini D, Lombardi R, Pennisi G, Ravaioli F, Armandi A, et al.
J Pers Med
. 2024 Jun;
14(6).
PMID: 38929789
Background: Artificial intelligence (AI)-based chatbots have shown promise in providing counseling to patients with metabolic dysfunction-associated steatotic liver disease (MASLD). While ChatGPT3.5 has demonstrated the ability to comprehensively answer MASLD-related...
5.
Lombardi R, Dalbeni A, Mantovani A, Ravaioli F
Hepatology
. 2024 Feb;
79(6):E155-E156.
PMID: 38349677
No abstract available.
6.
Bevilacqua M, De Marco L, Stupia R, Cattazzo F, Zoncape M, Paon V, et al.
Dig Liver Dis
. 2024 Jan;
56(9):1522-1528.
PMID: 38281869
Background And Aims: Acute-on-chronic liver failure (ACLF) is a severe complication of advanced liver disease. A significant number of ACLF patients have not clear precipitating factors. The aim of the...
7.
Ammendola S, Romeo S, Cattazzo F, Mantovani A, Ieluzzi D, Paon V, et al.
Int J Mol Sci
. 2024 Jan;
25(2).
PMID: 38255857
Twenty-nine patients with HCV infection (HCV+) and mixed cryoglobulinemia (MC+) were retrospectively selected and matched for age and sex with 31 HCV+ MC- patients. Biomarkers of cholestasis (direct bilirubin, alkaline...
8.
Dalbeni A, Mantovani A, Lombardi R, Ravaioli F
Hepatology
. 2023 Dec;
79(5):E146-E147.
PMID: 38088890
No abstract available.
9.
Sartorio A, Burrei G, Cristin L, Zoncape M, Carlin M, Tadiello E, et al.
Curr Vasc Pharmacol
. 2023 Dec;
22(2):106-121.
PMID: 38073101
Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes Coronavirus disease 2019 (COVID-19), characterized by pulmonary infection ranging from asymptomatic forms to respiratory insufficiency and death. Evidence of cardiac involvement...
10.
Stupia R, Lombardi R, Cattazzo F, Zoncape M, Mantovani A, De Marco L, et al.
J Thromb Thrombolysis
. 2023 Dec;
57(2):330-336.
PMID: 38066387
Portal vein thrombosis (PVT) is a common complication of cirrhosis as a result of portal hypertension and modification in the hemostatic balance. Accumulating evidence now suggests that patients with non-alcoholic...